Cancer biotech Cerulean files for a $75 million IPO

By
A A A

Cerulean Pharma, a clinical-stage biotech developing targeted cancer therapies for liver and ovarian cancer, filed on Monday with the SEC to raise up to $75 million in an initial public offering. The Cambridge, MA-based company, which was founded in 2005, plans to list on the NASDAQ under the symbol CERU. Cerulean initially filed confidentially on January 30, 2014. Leerink Partners is the sole bookrunner on the deal. No pricing terms were disclosed.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: CERU

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

100%

Most Active by Volume

111,864,163
  • $3.91 ▲ 2.36%
76,404,746
  • $7.37 ▼ 5.03%
66,680,057
  • $15.25 ▼ 2.12%
61,293,760
  • $30.55 ▼ 6.09%
56,394,825
    $23 unch
55,005,642
  • $95.60 ▼ 2.60%
47,372,853
  • $95.02 ▼ 2.02%
44,783,481
  • $45.19 ▼ 2.40%
As of 7/31/2014, 04:07 PM